{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:44:21Z","timestamp":1795031061784,"version":"4.10.2"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41579-022-00789-8","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T14:03:56Z","timestamp":1662991436000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Lassa fever \u2014 the road ahead"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-3250","authenticated-orcid":false,"given":"Robert F.","family":"Garry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","volume":"162","author":"KG Andersen","year":"2015","unstructured":"Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738\u2013750 (2015).","journal-title":"Cell"},{"key":"789_CR2","first-page":"1352","volume":"71","author":"L Pinneo","year":"1971","unstructured":"Pinneo, L. & Pinneo, R. Mystery virus from Lassa. Am. J. Nurs. 71, 1352\u20131355 (1971).","journal-title":"Am. J. Nurs."},{"key":"789_CR3","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(12)61871-6","volume":"380","author":"GM Watts","year":"2013","unstructured":"Watts, G. M. Lily Lyman Pinneo. Lancet 380, 1552 (2013).","journal-title":"Lancet"},{"key":"789_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.4269\/ajtmh.1970.19.677","volume":"19","author":"E Leifer","year":"1970","unstructured":"Leifer, E., Gocke, D. J. & Bourne, H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19, 677\u2013679 (1970).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"789_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/227174a0","volume":"227","author":"SM Buckley","year":"1970","unstructured":"Buckley, S. M., Casals, J. & Downs, W. G. Isolation and antigenic characterization of Lassa virus. Nature 227, 174 (1970). This work reports the initial isolation and characterization of Lassa virus.","journal-title":"Nature"},{"key":"789_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.4269\/ajtmh.1970.19.680","volume":"19","author":"SM Buckley","year":"1970","unstructured":"Buckley, S. M. & Casals, J. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 19, 680\u2013691 (1970).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"789_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.185.4147.263","volume":"185","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263\u2013265 (1974). This work is the first demonstration that Lassa virus is rodent-borne.","journal-title":"Science"},{"key":"789_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/vbz.2013.1484","volume":"14","author":"E Fichet-Calvet","year":"2014","unstructured":"Fichet-Calvet, E., Becker-Ziaja, B., Koivogui, L. & Gunther, S. Lassa serology in natural populations of rodents and horizontal transmission. Vector Borne Zoonotic Dis. 14, 665\u2013674 (2014).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/vbz.2007.0118","volume":"8","author":"E Fichet-Calvet","year":"2008","unstructured":"Fichet-Calvet, E., Lecompte, E., Koivogui, L., Daffis, S. & ter Meulen, J. Reproductive characteristics of Mastomys natalensis and Lassa virus prevalence in Guinea, West Africa. Vector Borne Zoonotic Dis. 8, 41\u201348 (2008).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1089\/hs.2019.0080","volume":"18","author":"CG Kaka\u012b","year":"2020","unstructured":"Kaka\u012b, C. G. et al. Improving cross-border preparedness and response: lessons learned from 3 lassa fever outbreaks across Benin, Nigeria, and Togo, 2017\u20132019. Health Secur. 18, S105\u2013S112 (2020).","journal-title":"Health Secur."},{"key":"789_CR11","first-page":"8242313","volume":"2017","author":"AA Patassi","year":"2017","unstructured":"Patassi, A. A. et al. Emergence of lassa fever disease in northern Togo: report of two cases in Oti district in 2016. Case Rep. Infect. Dis. 2017, 8242313 (2017).","journal-title":"Case Rep. Infect. Dis."},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","volume":"59","author":"N Sogoba","year":"2012","unstructured":"Sogoba, N., Feldmann, H. & Safronetz, D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health 59, 43\u201347 (2012).","journal-title":"Zoonoses Public Health"},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","volume":"141","author":"PB Jahrling","year":"1980","unstructured":"Jahrling, P. B. et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141, 580\u2013589 (1980). This work presents the development of a non-human primate model.","journal-title":"J. Infect. Dis."},{"key":"789_CR14","first-page":"5","volume":"134","author":"CJ Peters","year":"1987","unstructured":"Peters, C. J. et al. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134, 5\u201368 (1987).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/fvl.15.41","volume":"10","author":"JN Hartnett","year":"2015","unstructured":"Hartnett, J. N. et al. Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virol. 10, 559\u2013584 (2015).","journal-title":"Future Virol."},{"key":"789_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw239","author":"A Goba","year":"2016","unstructured":"Goba, A. et al. An outbreak of Ebola virus disease in the Lassa fever zone. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiw239 (2016).","journal-title":"J. Infect. Dis."},{"key":"789_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res. 133, 218\u2013222 (2016). This work presents the initial characterization of Lassa virus monoclonal antibodies in animals.","journal-title":"Antivir. Res."},{"key":"789_CR18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"789_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","volume":"90","author":"KA Cashman","year":"2011","unstructured":"Cashman, K. A. et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antivir. Res. 90, 70\u201379 (2011).","journal-title":"Antivir. Res."},{"key":"789_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040772","author":"F Hansen","year":"2021","unstructured":"Hansen, F., Jarvis, M. A., Feldmann, H. & Rosenke, K. Lassa virus treatment options. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms9040772 (2021).","journal-title":"Microorganisms"},{"key":"789_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.coviro.2019.07.006","volume":"37","author":"K Salami","year":"2019","unstructured":"Salami, K., Gouglas, D., Schmaljohn, C., Saville, M. & Tornieporth, N. A review of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105\u2013111 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"789_CR22","first-page":"7","volume":"18","author":"TV Gale","year":"2019","unstructured":"Gale, T. V., Horton, T. M., Hoffmann, A. R., Branco, L. M. & Garry, R. F. Host proteins identified in extracellular viral particles as targets for broad-spectrum antiviral inhibitors. J. Proteome Res. 18, 7\u201317 (2019).","journal-title":"J. Proteome Res."},{"key":"789_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/jvi.5.5.651-652.1970","volume":"5","author":"WP Rowe","year":"1970","unstructured":"Rowe, W. P. et al. Arenoviruses: proposed name for a newly defined virus group. J. Virol. 5, 651\u2013652 (1970).","journal-title":"J. Virol."},{"key":"789_CR24","first-page":"V","volume":"262","author":"MB Oldstone","year":"2002","unstructured":"Oldstone, M. B. Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction. Curr. Top. Microbiol. Immunol. 262, V\u2013XII (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"789_CR25","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1073\/pnas.1016404108","volume":"108","author":"KM Hastie","year":"2011","unstructured":"Hastie, K. M., Kimberlin, C. R., Zandonatti, M. A., MacRae, I. J. & Saphire, E. O. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3\u2032 to 5\u2032 exonuclease activity essential for immune suppression. Proc. Natl Acad. Sci. USA 108, 2396\u20132401 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044211","volume":"7","author":"KM Hastie","year":"2012","unstructured":"Hastie, K. M., King, L. B., Zandonatti, M. A. & Saphire, E. O. Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease. PloS ONE 7, e44211 (2012).","journal-title":"PloS ONE"},{"key":"789_CR27","doi-asserted-by":"publisher","first-page":"19365","DOI":"10.1073\/pnas.1108515108","volume":"108","author":"KM Hastie","year":"2011","unstructured":"Hastie, K. M. et al. Crystal structure of the Lassa virus nucleoprotein\u2013RNA complex reveals a gating mechanism for RNA binding. Proc. Natl Acad. Sci. USA 108, 19365\u201319370 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.05.002","author":"KM Hastie","year":"2018","unstructured":"Hastie, K. M. & Saphire, E. O. Lassa virus glycoprotein: stopping a moving target. Curr. Opin. Virol. https:\/\/doi.org\/10.1016\/j.coviro.2018.05.002 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"789_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27305-5","volume":"12","author":"T Kouba","year":"2021","unstructured":"Kouba, T. et al. Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity. Nat. Commun. 12, 7018 (2021).","journal-title":"Nat. Commun."},{"key":"789_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41564-021-00916-w","volume":"6","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Cryo-EM structures of Lassa and Machupo virus polymerases complexed with cognate regulatory Z proteins identify targets for antivirals. Nat. Microbiol. 6, 921\u2013931 (2021).","journal-title":"Nat. Microbiol."},{"key":"789_CR31","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1128\/JVI.02896-15","volume":"90","author":"KM Hastie","year":"2016","unstructured":"Hastie, K. M. et al. Crystal structure of the oligomeric form of Lassa virus matrix protein Z. J. Virol. 90, 4556\u20134562 (2016).","journal-title":"J. Virol."},{"key":"789_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/v13091679","author":"S Joseph","year":"2021","unstructured":"Joseph, S. & Campbell, K. P. Lassa fever virus binds matriglycan-A polymer of alternating xylose and glucuronate-on \u03b1-dystroglycan. Viruses https:\/\/doi.org\/10.3390\/v13091679 (2021).","journal-title":"Viruses"},{"key":"789_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00093-18","author":"RB Brouillette","year":"2018","unstructured":"Brouillette, R. B. et al. TIM-1 mediates dystroglycan-independent entry of Lassa virus. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00093-18 (2018).","journal-title":"J. Virol."},{"key":"789_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/v12080857","author":"C Fedeli","year":"2020","unstructured":"Fedeli, C., Moreno, H. & Kunz, S. The role of receptor tyrosine kinases in lassa virus cell entry. Viruses https:\/\/doi.org\/10.3390\/v12080857 (2020).","journal-title":"Viruses"},{"key":"789_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01613-17","author":"C Fedeli","year":"2018","unstructured":"Fedeli, C. et al. Axl can serve as entry factor for Lassa virus depending on the functional glycosylation of dystroglycan. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01613-17 (2018).","journal-title":"J. Virol."},{"key":"789_CR36","doi-asserted-by":"publisher","first-page":"11504","DOI":"10.1128\/JVI.01893-13","volume":"87","author":"AR Goncalves","year":"2013","unstructured":"Goncalves, A. R. et al. Role of DC-SIGN in Lassa virus entry into human dendritic cells. J. Virol. 87, 11504\u201311515 (2013).","journal-title":"J. Virol."},{"key":"789_CR37","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1126\/science.282.5396.2079","volume":"282","author":"W Cao","year":"1998","unstructured":"Cao, W. et al. Identification of \u03b1-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282, 2079\u20132081 (1998).","journal-title":"Science"},{"key":"789_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005418","volume":"12","author":"S Li","year":"2016","unstructured":"Li, S. et al. Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike. PloS Pathog. 12, e1005418 (2016).","journal-title":"PloS Pathog."},{"key":"789_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006337","volume":"13","author":"H Israeli","year":"2017","unstructured":"Israeli, H., Cohen-Dvashi, H., Shulman, A., Shimon, A. & Diskin, R. Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses. PloS Pathog. 13, e1006337 (2017).","journal-title":"PloS Pathog."},{"key":"789_CR40","unstructured":"Radoshitzky, S. R., Buchmeier, M. J. & de la Torre, J. C. in Field\u2019s Virology 7th edn Vol. 1 Ch. 18 (eds Howley, P. M. & Knipe, D. M.) (Lippincott Williams & Wilkins, 2020)."},{"key":"789_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0042-6822(86)90438-1","volume":"154","author":"DD Auperin","year":"1986","unstructured":"Auperin, D. D., Sasso, D. R. & McCormick, J. B. Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology 154, 155\u2013167 (1986).","journal-title":"Virology"},{"key":"789_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005636","volume":"12","author":"J Reguera","year":"2016","unstructured":"Reguera, J. et al. Comparative structural and functional analysis of Bunyavirus and Arenavirus cap-snatching endonucleases. PloS Pathog. 12, e1005636 (2016).","journal-title":"PloS Pathog."},{"key":"789_CR43","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923\u2013928 (2017). This work reveals the structure of the native trimeric structure of the Lassa virus glycoprotein.","journal-title":"Science"},{"key":"789_CR44","doi-asserted-by":"publisher","first-page":"12701","DOI":"10.1073\/pnas.221447598","volume":"98","author":"O Lenz","year":"2001","unstructured":"Lenz, O., ter Meulen, J., Klenk, H. D., Seidah, N. G. & Garten, W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1\/S1P. Proc. Natl Acad. Sci. USA 98, 12701\u201312705 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR45","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/v4102049","volume":"4","author":"SU Yasuda","year":"2012","unstructured":"Yasuda, S. U. & Jiro Molecular mechanism of arenavirus assembly and budding. Viruses 4, 2049\u20132079 (2012).","journal-title":"Viruses"},{"key":"789_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00929-19","author":"DU Ehichioya","year":"2019","unstructured":"Ehichioya, D. U. et al. Phylogeography of Lassa virus in Nigeria. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00929-19 (2019).","journal-title":"J. Virol."},{"key":"789_CR47","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","volume":"74","author":"MD Bowen","year":"2000","unstructured":"Bowen, M. D. et al. Genetic diversity among Lassa virus strains. J. Virol. 74, 6992\u20137004 (2000). This work examines Lassa virus phylogeny.","journal-title":"J. Virol."},{"key":"789_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.11604\/pamj.2016.23.210.8923","volume":"23","author":"KC Mofolorunsho","year":"2016","unstructured":"Mofolorunsho, K. C. Outbreak of lassa fever in Nigeria: measures for prevention and control. Pan Afr. Med. J. 23, 210 (2016).","journal-title":"Pan Afr. Med. J."},{"key":"789_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2055-6640(20)30306-X","volume":"4","author":"HO Akhiwu","year":"2018","unstructured":"Akhiwu, H. O. et al. Lassa fever outbreak in adolescents in north central Nigeria: report of cases. J. Virus Erad. 4, 225\u2013227 (2018).","journal-title":"J. Virus Erad."},{"key":"789_CR50","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14787210.2018.1512856","volume":"16","author":"GO Akpede","year":"2018","unstructured":"Akpede, G. O., Asogun, D. A., Okogbenin, S. A. & Okokhere, P. O. Lassa fever outbreaks in Nigeria. Expert Rev. Anti Infect. Ther. 16, 663\u2013666 (2018).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"789_CR51","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3201\/eid2506.181035","volume":"25","author":"EA Ilori","year":"2019","unstructured":"Ilori, E. A. et al. Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1\u2013May 6, 2018. Emerg. Infect. Dis. 25, 1066\u20131074 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/d41586-018-03171-y","volume":"555","author":"A Maxmen","year":"2018","unstructured":"Maxmen, A. Deadly Lassa-fever outbreak tests Nigeria\u2019s revamped health agency. Nature 555, 421\u2013422 (2018).","journal-title":"Nature"},{"key":"789_CR53","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","volume":"379","author":"KJ Siddle","year":"2018","unstructured":"Siddle, K. J. et al. Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018. N. Engl. J. Med. 379, 1745\u20131753 (2018).","journal-title":"N. Engl. J. Med."},{"key":"789_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fmicb.2015.01037","volume":"6","author":"JT Manning","year":"2015","unstructured":"Manning, J. T., Forrester, N. & Paessler, S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front. Microbiol. 6, 1037 (2015).","journal-title":"Front. Microbiol."},{"key":"789_CR55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3201\/eid2403.171905","volume":"24","author":"SLM Whitmer","year":"2018","unstructured":"Whitmer, S. L. M. et al. New lineage of Lassa virus, Togo, 2016. Emerg. Infect. Dis. 24, 599\u2013602 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/vim.2014.0108","volume":"28","author":"ML Boisen","year":"2015","unstructured":"Boisen, M. L. et al. Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol. 28, 19\u201331 (2015).","journal-title":"Viral Immunol."},{"key":"789_CR57","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","volume":"327","author":"JK Richmond","year":"2003","unstructured":"Richmond, J. K. & Baglole, D. J. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327, 1271\u20131275 (2003).","journal-title":"BMJ"},{"key":"789_CR58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3201\/eid1205.050052","volume":"12","author":"AM Macher","year":"2006","unstructured":"Macher, A. M. & Wolfe, M. S. Historical Lassa fever reports and 30-year clinical update. Emerg. Infect. Dis. 12, 835\u2013837 (2006).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa035","author":"T Wolf","year":"2020","unstructured":"Wolf, T., Ellwanger, R., Goetsch, U., Wetzstein, N. & Gottschalk, R. Fifty years of imported Lassa fever\u2013a systematic review of primary and secondary cases. J. Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taaa035 (2020).","journal-title":"J. Travel Med."},{"key":"789_CR60","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2017.22.39.16-00728","author":"L Ehlkes","year":"2017","unstructured":"Ehlkes, L. et al. Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. Eur. Surveill. https:\/\/doi.org\/10.2807\/1560-7917.Es.2017.22.39.16-00728 (2017).","journal-title":"Eur. Surveill."},{"key":"789_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ijid.2022.02.020","volume":"117","author":"C Njuguna","year":"2022","unstructured":"Njuguna, C. et al. A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands. Int. J. Infect. Dis. 117, 295\u2013301 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"789_CR62","unstructured":"WHO. Lassa fever\u2013United Kingdom of Great Britain and Northern Ireland. World Health Organization https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/lassa-fever-united-kingdom-of-great-britain-and-northern-ireland (2022)."},{"key":"789_CR63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002324118","volume":"118","author":"Z Grange","year":"2021","unstructured":"Grange, Z. L. et al. Ranking the risk of animal-to-human spillover for newly discovered viruses. Proc. Natl Acad. Sci. USA 118, e2002324118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/82_2020_231","author":"AR Smither","year":"2021","unstructured":"Smither, A. R. & Bell-Kareem, A. R. Ecology of Lassa virus. Curr. Top. Microbiol. Immunol. https:\/\/doi.org\/10.1007\/82_2020_231 (2021).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"789_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002748","volume":"8","author":"JG Shaffer","year":"2014","unstructured":"Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PloS Negl. Trop. Dis. 8, e2748 (2014).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR66","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4269\/ajtmh.16-0675","volume":"96","author":"J Bonwitt","year":"2017","unstructured":"Bonwitt, J. et al. At home with Mastomys and Rattus: human\u2013rodent interactions and potential for primary transmission of Lassa virus in domestic spaces. Am. J. Trop. Med. Hyg. 96, 935\u2013943 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"789_CR67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10393-016-1098-8","volume":"13","author":"J Bonwitt","year":"2016","unstructured":"Bonwitt, J. et al. Rat-atouille: a mixed method study to characterize rodent hunting and consumption in the context of Lassa fever. EcoHealth 13, 234\u2013247 (2016).","journal-title":"EcoHealth"},{"key":"789_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006829","volume":"12","author":"A Mari Saez","year":"2018","unstructured":"Mari Saez, A. et al. Rodent control to fight Lassa fever: evaluation and lessons learned from a 4-year study in Upper Guinea. PloS Negl. Trop. Dis. 12, e0006829 (2018).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR69","unstructured":"WHO. Lassa fever. World Health Organization https:\/\/www.who.int\/health-topics\/lassa-fever#tab=tab_1 (2022)."},{"key":"789_CR70","first-page":"389","volume":"31","author":"J Knobloch","year":"1980","unstructured":"Knobloch, J. et al. Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol. 31, 389\u2013398 (1980).","journal-title":"Tropenmed Parasitol."},{"key":"789_CR71","first-page":"75","volume":"262","author":"JB McCormick","year":"2002","unstructured":"McCormick, J. B. & Fisher-Hoch, S. P. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75\u2013109 (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"789_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005711","volume":"11","author":"OC Akhuemokhan","year":"2017","unstructured":"Akhuemokhan, O. C. et al. Prevalence of Lassa virus disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area. PloS Negl. Trop. Dis. 11, e0005711 (2017).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR73","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","volume":"18","author":"P Okokhere","year":"2018","unstructured":"Okokhere, P. et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect. Dis. 18, 684\u2013695 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"789_CR74","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/j.1365-3156.2012.03010.x","volume":"17","author":"DU Ehichioya","year":"2012","unstructured":"Ehichioya, D. U. et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005\u20132008. Trop. Med. Int. Health 17, 1001\u20131004 (2012).","journal-title":"Trop. Med. Int. Health"},{"key":"789_CR75","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","volume":"108","author":"MI Buba","year":"2018","unstructured":"Buba, M. I. et al. Mortality among confirmed lassa fever cases during the 2015\u20132016 outbreak in Nigeria. Am. J. Public Health 108, 262\u2013264 (2018).","journal-title":"Am. J. Public Health"},{"key":"789_CR76","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1743-422X-8-404","volume":"8","author":"LM Branco","year":"2011","unstructured":"Branco, L. M. et al. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol. J. 8, 404 (2011).","journal-title":"Virol. J."},{"key":"789_CR77","doi-asserted-by":"publisher","DOI":"10.3201\/eid2508.181299","author":"S Okogbenin","year":"2019","unstructured":"Okogbenin, S. et al. Retrospective cohort study of Lassa fever in pregnancy, southern Nigeria. Emerg. Infect. Dis. https:\/\/doi.org\/10.3201\/eid2508.181299 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR78","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3201\/eid2505.181247","volume":"25","author":"EA Ilori","year":"2019","unstructured":"Ilori, E. A. et al. Increase in Lassa fever cases in Nigeria, January\u2013March 2018. Emerg. Infect. Dis. 25, 1026\u20131027 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2020.08.021","volume":"100","author":"SC Ficenec","year":"2020","unstructured":"Ficenec, S. C. et al. Lassa fever induced hearing loss: the neglected disability of hemorrhagic fever. Int. J. Infect. Dis. 100, 82\u201387 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"789_CR80","doi-asserted-by":"publisher","first-page":"484","DOI":"10.4269\/ajtmh.18-0934","volume":"101","author":"SC Ficenec","year":"2019","unstructured":"Ficenec, S. C., Schieffelin, J. S. & Emmett, S. D. A review of hearing loss associated with Zika, Ebola, and Lassa fever. Am. J. Trop. Med. Hyg. 101, 484\u2013490 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"789_CR81","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2019.12.022","volume":"92","author":"A Duvignaud","year":"2020","unstructured":"Duvignaud, A. et al. Delayed-onset paraparesis in Lassa fever: a case report. Int. J. Infect. Dis. 92, 49\u201352 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"789_CR82","doi-asserted-by":"publisher","first-page":"ofz512","DOI":"10.1093\/ofid\/ofz512","volume":"6","author":"C Ezeomah","year":"2019","unstructured":"Ezeomah, C. et al. Sequelae of Lassa fever: postviral cerebellar ataxia. Open Forum Infect. Dis. 6, ofz512 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"789_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243766","volume":"15","author":"AL Li","year":"2020","unstructured":"Li, A. L. et al. Ophthalmic manifestations and vision impairment in Lassa fever survivors. PloS ONE 15, e0243766 (2020).","journal-title":"PloS ONE"},{"key":"789_CR84","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/d41586-021-02378-w","volume":"597","author":"RF Garry","year":"2021","unstructured":"Garry, R. F. Ebola virus can lie low and reactivate after years in human survivors. Nature 597, 478\u2013480 (2021).","journal-title":"Nature"},{"key":"789_CR85","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijid.2017.09.013","volume":"64","author":"H Lee","year":"2017","unstructured":"Lee, H. & Nishiura, H. Recrudescence of Ebola virus disease outbreak in West Africa, 2014\u20132016. Int. J. Infect. Dis. 64, 90\u201392 (2017).","journal-title":"Int. J. Infect. Dis."},{"key":"789_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314, 20\u201326 (1986). This work reports a treatment study with ribavirin in humans.","journal-title":"N. Engl. J. Med."},{"key":"789_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.07.015","author":"KA Eberhardt","year":"2019","unstructured":"Eberhardt, K. A. et al. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int. J. Infect. Dis. https:\/\/doi.org\/10.1016\/j.ijid.2019.07.015 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"789_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009522","volume":"15","author":"AP Salam","year":"2021","unstructured":"Salam, A. P. et al. Time to reconsider the role of ribavirin in Lassa fever. PloS Negl. Trop. Dis. 15, e0009522 (2021).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.coviro.2012.01.003","volume":"2","author":"KM Hastie","year":"2012","unstructured":"Hastie, K. M., Bale, S., Kimberlin, C. R. & Saphire, E. O. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2, 151\u2013156 (2012).","journal-title":"Curr. Opin. Virol."},{"key":"789_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/v12090907","author":"Q Huang","year":"2020","unstructured":"Huang, Q., Liu, X., Brisse, M., Ly, H. & Liang, Y. Effect of strain variations on Lassa virus Z protein-mediated human RIG-I inhibition. Viruses https:\/\/doi.org\/10.3390\/v12090907 (2020).","journal-title":"Viruses"},{"key":"789_CR91","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1073\/pnas.1803990115","volume":"115","author":"Y Watanabe","year":"2018","unstructured":"Watanabe, Y. et al. Structure of the Lassa virus glycan shield provides a model for immunological resistance. Proc. Natl Acad. Sci. USA 115, 7320\u20137325 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR92","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/1743-422X-8-478","volume":"8","author":"LM Branco","year":"2011","unstructured":"Branco, L. M. et al. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol. J. 8, 478 (2011).","journal-title":"Virol. J."},{"key":"789_CR93","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2016.138","volume":"17","author":"JB Prescott","year":"2017","unstructured":"Prescott, J. B. et al. Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol. 17, 195\u2013207 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"789_CR94","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00153-20","author":"S Sakabe","year":"2020","unstructured":"Sakabe, S. et al. Identification of common CD8+ T cell epitopes from Lassa fever survivors in Nigeria and Sierra Leone. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00153-20 (2020).","journal-title":"J. Virol."},{"key":"789_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008352","volume":"16","author":"BM Sullivan","year":"2020","unstructured":"Sullivan, B. M. et al. High crossreactivity of human T cell responses between Lassa virus lineages. PloS Pathog. 16, e1008352 (2020).","journal-title":"PloS Pathog."},{"key":"789_CR96","doi-asserted-by":"publisher","first-page":"8351","DOI":"10.1128\/JVI.00896-06","volume":"80","author":"J Botten","year":"2006","unstructured":"Botten, J. et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. 80, 8351\u20138361 (2006).","journal-title":"J. Virol."},{"key":"789_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000836","volume":"6","author":"L Flatz","year":"2010","unstructured":"Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PloS Pathog. 6, e1000836 (2010).","journal-title":"PloS Pathog."},{"key":"789_CR98","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01367-20","author":"JR Port","year":"2020","unstructured":"Port, J. R. et al. Severe human Lassa fever is characterized by nonspecific T-cell activation and lymphocyte homing to inflamed tissues. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01367-20 (2020).","journal-title":"J. Virol."},{"key":"789_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001839","volume":"6","author":"DA Asogun","year":"2012","unstructured":"Asogun, D. A. et al. Molecular diagnostics for lassa fever at Irrua Specialist Teaching Hospital, Nigeria: lessons learnt from two years of laboratory operation. PloS Negl. Trop. Dis. 6, e1839 (2012).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24246-w","volume":"8","author":"ML Boisen","year":"2018","unstructured":"Boisen, M. L. et al. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci. Rep. 8, 5939 (2018).","journal-title":"Sci. Rep."},{"key":"789_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65736-0","volume":"10","author":"ML Boisen","year":"2020","unstructured":"Boisen, M. L. et al. Field evaluation of a pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Sci. Rep. 10, 8724 (2020).","journal-title":"Sci. Rep."},{"key":"789_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72539-w","volume":"10","author":"ML Heinrich","year":"2020","unstructured":"Heinrich, M. L. et al. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Sci. Rep. 10, 16030 (2020).","journal-title":"Sci. Rep."},{"key":"789_CR103","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 449\u2013463 (2017).","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"789_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).","journal-title":"Sci. Rep."},{"key":"789_CR105","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/infdis\/jiv522","volume":"213","author":"L Oestereich","year":"2016","unstructured":"Oestereich, L. et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J. Infect. Dis. 213, 934\u2013938 (2016).","journal-title":"J. Infect. Dis."},{"key":"789_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008535","volume":"17","author":"G Lingas","year":"2021","unstructured":"Lingas, G., Rosenke, K., Safronetz, D. & Guedj, J. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PloS Comput. Biol. 17, e1008535 (2021).","journal-title":"PloS Comput. Biol."},{"key":"789_CR107","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3201\/eid2409.180233","volume":"24","author":"K Rosenke","year":"2018","unstructured":"Rosenke, K. et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg. Infect. Dis. 24, 1696\u20131699 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001342","volume":"5","author":"M Mendenhall","year":"2011","unstructured":"Mendenhall, M. et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PloS Negl. Trop. Dis. 5, e1342 (2011).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR109","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1743-422X-7-240","volume":"7","author":"BB Gowen","year":"2010","unstructured":"Gowen, B. B. et al. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J. 7, 240 (2010).","journal-title":"Virol. J."},{"key":"789_CR110","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/cid\/cix406","volume":"65","author":"VN Raabe","year":"2017","unstructured":"Raabe, V. N. et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin. Infect. Dis. 65, 855\u2013859 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"789_CR111","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1128\/JVI.00941-08","volume":"82","author":"RA Larson","year":"2008","unstructured":"Larson, R. A. et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82, 10768\u201310775 (2008).","journal-title":"J. Virol."},{"key":"789_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).","journal-title":"Nat. Commun."},{"key":"789_CR113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coviro.2019.07.003","volume":"37","author":"RW Cross","year":"2019","unstructured":"Cross, R. W. et al. Antibody therapy for Lassa fever. Curr. Opin. Virol. 37, 97\u2013104 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"789_CR114","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","volume":"178","author":"KM Hastie","year":"2019","unstructured":"Hastie, K. M. et al. Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization. Cell 178, 1004\u20131015.e14 (2019).","journal-title":"Cell"},{"key":"789_CR115","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01278-22","author":"TK Buck","year":"2022","unstructured":"Buck, T. K. et al. Neutralizing antibodies against lassa virus lineage I. mBio https:\/\/doi.org\/10.1128\/mbio.01278-22 (2022).","journal-title":"mBio"},{"key":"789_CR116","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03347-21","volume":"12","author":"JM White","year":"2021","unstructured":"White, J. M. et al. Drug combinations as a first line of defense against coronaviruses and other emerging viruses. mBio 12, e0334721 (2021).","journal-title":"mBio"},{"key":"789_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/v13020214","author":"DM Johnson","year":"2021","unstructured":"Johnson, D. M., Cubitt, B., Pfeffer, T. L., de la Torre, J. C. & Lukashevich, I. S. Lassa virus vaccine candidate ML29 generates truncated viral RNAs which contribute to interfering activity and attenuation. Viruses https:\/\/doi.org\/10.3390\/v13020214 (2021).","journal-title":"Viruses"},{"key":"789_CR118","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccines Immunother. 13, 2902\u20132911 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"789_CR119","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI131958","volume":"130","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539\u2013551 (2020).","journal-title":"J. Clin. Invest."},{"key":"789_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0104-x","volume":"4","author":"DR Stein","year":"2019","unstructured":"Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4, 8 (2019).","journal-title":"NPJ Vaccines"},{"key":"789_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa\u2013rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).","journal-title":"Nat. Commun."},{"key":"789_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf6348","author":"M Mateo","year":"2021","unstructured":"Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abf6348 (2021).","journal-title":"Sci. Transl Med."},{"key":"789_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8030133","author":"MS Salvato","year":"2019","unstructured":"Salvato, M. S. et al. A single dose of modified vaccinia ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge. Pathogens https:\/\/doi.org\/10.3390\/pathogens8030133 (2019).","journal-title":"Pathogens"},{"key":"789_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/v13030484","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Construction and immunological evaluation of an adenoviral vector-based vaccine candidate for Lassa fever. Viruses https:\/\/doi.org\/10.3390\/v13030484 (2021).","journal-title":"Viruses"},{"key":"789_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00291-x","volume":"6","author":"RJ Fischer","year":"2021","unstructured":"Fischer, R. J. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines 6, 32 (2021).","journal-title":"NPJ Vaccines"},{"key":"789_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00219-x","volume":"5","author":"H M\u00fcller","year":"2020","unstructured":"M\u00fcller, H. et al. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. NPJ Vaccines 5, 71 (2020).","journal-title":"NPJ Vaccines"},{"key":"789_CR127","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1743-422X-7-279","volume":"7","author":"LM Branco","year":"2010","unstructured":"Branco, L. M. et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 7, 279 (2010).","journal-title":"Virol. J."},{"key":"789_CR128","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/infdis\/jiz284","volume":"220","author":"MH Kainulainen","year":"2019","unstructured":"Kainulainen, M. H. et al. Protection from lethal Lassa disease can be achieved both before and after virus exposure by administration of single-cycle replicating Lassa virus replicon particles. J. Infect. Dis. 220, 1281\u20131289 (2019).","journal-title":"J. Infect. Dis."},{"key":"789_CR129","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/epirev\/mxz012","volume":"41","author":"D Gouglas","year":"2019","unstructured":"Gouglas, D., Christodoulou, M., Plotkin, S. A. & Hatchett, R. CEPI: driving progress toward epidemic preparedness and response. Epidemiol. Rev. 41, 28\u201333 (2019).","journal-title":"Epidemiol. Rev."},{"key":"789_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009576","volume":"15","author":"MR Koch","year":"2021","unstructured":"Koch, M. R. et al. Health seeking behavior after the 2013\u201316 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. PloS Negl. Trop. Dis. 15, e0009576 (2021).","journal-title":"PloS Negl. Trop. Dis."},{"key":"789_CR131","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1128\/JVI.03049-15","volume":"90","author":"B Meyer","year":"2016","unstructured":"Meyer, B. & Ly, H. Inhibition of innate immune responses is key to pathogenesis by arenaviruses. J. Virol. 90, 3810\u20133818 (2016).","journal-title":"J. Virol."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00789-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00789-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00789-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:34:33Z","timestamp":1733956473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00789-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1038\/s41579-022-00789-8","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"5 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.F.G. is the co-founder of Zalgen Labs, a biotechnology company developing countermeasures for Lassa virus (LASV) and other emerging viruses.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}